Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.20)
# 2,711
Out of 4,876 analysts
108
Total ratings
46.43%
Success rate
-4.81%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Outperform | $175 → $180 | $167.18 | +7.67% | 7 | Jun 12, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $8.41 | -16.77% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $188.52 | +6.09% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $177.83 | +1.22% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $3.81 | +4.99% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $4.98 | +201.20% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $725.78 | -7.00% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $68.49 | -5.10% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.45 | +4.80% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $260.59 | +1.69% | 4 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $15.93 | +25.55% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $39.76 | -9.46% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $157.47 | +68.29% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $61.09 | -26.34% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $2.31 | +73.16% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $19.67 | +16.93% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $22.00 | -9.09% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.70 | +360.53% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.18 | +258.85% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.30 | +378.26% | 2 | Jan 4, 2022 |
Cardinal Health
Jun 12, 2025
Maintains: Outperform
Price Target: $175 → $180
Current: $167.18
Upside: +7.67%
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $8.41
Upside: -16.77%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $188.52
Upside: +6.09%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $177.83
Upside: +1.22%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $3.81
Upside: +4.99%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $4.98
Upside: +201.20%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $725.78
Upside: -7.00%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $68.49
Upside: -5.10%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.45
Upside: +4.80%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $260.59
Upside: +1.69%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.93
Upside: +25.55%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $39.76
Upside: -9.46%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $157.47
Upside: +68.29%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $61.09
Upside: -26.34%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $2.31
Upside: +73.16%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $19.67
Upside: +16.93%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $22.00
Upside: -9.09%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.70
Upside: +360.53%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.18
Upside: +258.85%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.30
Upside: +378.26%